Skip to main content

Tepadina Disease Interactions

There are 4 disease interactions with Tepadina (thiotepa).

Major

Antineoplastics (applies to Tepadina) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. (2002) "Product Information. Methotrexate (methotrexate)." Lederle Laboratories
  2. (2001) "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb
  3. (2001) "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb
  4. (2001) "Product Information. Novantrone (mitoxantrone)." Immunex Corporation
  5. (2001) "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb
  6. (2001) "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb
  7. (2001) "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)
  8. (2001) "Product Information. Fludara (fludarabine)." Berlex Laboratories
  9. (2001) "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn
  10. (2001) "Product Information. Matulane (procarbazine)." Roche Laboratories
  11. (2001) "Product Information. DTIC-Dome (dacarbazine)." Bayer
  12. (2001) "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn
  13. (2001) "Product Information. Leustatin (cladribine)." Ortho Biotech Inc
  14. (2001) "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company
  15. (2001) "Product Information. Hycamtin (topotecan)." SmithKline Beecham
  16. (2001) "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer
  17. (2001) "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb
  18. (2001) "Product Information. Nipent (pentostatin)." Hospira Inc
  19. (2001) "Product Information. Tabloid (thioguanine)." Prasco Laboratories
  20. (2001) "Product Information. Xeloda (capecitabine)." Roche Laboratories
  21. (2022) "Product Information. Alkeran (melphalan)." Glaxo Wellcome
  22. (2001) "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. (2001) "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc
  25. (2001) "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn
  26. (2001) "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation
  27. (2010) "Product Information. Jevtana (cabazitaxel)." sanofi-aventis
  28. (2010) "Product Information. Halaven (eribulin)." Eisai Inc
  29. (2021) "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.
View all 29 references
Major

Thiotepa (applies to Tepadina) hepatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease

Thiotepa is rapidly metabolized by the liver to a biologically active form. The pharmacokinetic disposition of thiotepa has not be evaluated in patients with hepatic dysfunction. The use of thiotepa may be contraindicated in patients with existing hepatic damage. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Clinical monitoring of hepatic function is recommended.

References

  1. (2001) "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)
Major

Thiotepa (applies to Tepadina) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Fever, Bleeding, Bone Marrow Depression/Low Blood Counts

Thiotepa induces dose-related myelosuppression. Therapy with thiotepa should be withheld if a white blood cell count falls below 3000/mm3 or a platelet count falls below 150,000/mm3. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

References

  1. Soloway MS, Ford KS (1983) "Thiotepa-induced myelosuppression: review of 670 bladder instillations." J Urol, 130, p. 889-91
  2. Watkins WE, Kozak JA, Flanagan MJ (1967) "Severe pancytopenia associated with the use of intravesical thio- TEPA." J Urol, 98, p. 470-1
  3. Hollister D Jr, Coleman M (1980) "Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma." JAMA, 244, p. 2065-7
  4. Agnelli G, de Cunto M, Gresele P, del Favero A (1982) "Early onset life-threatening myelosuppression after low dose of intravesical thiotepa." Postgrad Med J, 58, p. 380-1
View all 4 references
Major

Thiotepa (applies to Tepadina) renal dysfunction

Major Potential Hazard, High plausibility.

Approximately 25% of thiotepa is eliminated by the kidney and <2% is eliminated unchanged in the urine. The pharmacokinetic disposition of thiotepa has not be evaluated in patients with renal dysfunction. The use of thiotepa may be contraindicated in patients with existing renal dysfunction. If the need outweighs the risk, extreme caution should be exercised in administering thiotepa and therapy should be initiated at a reduced dosage. Clinical monitoring of renal function is recommended.

References

  1. Schellhammer PF (1973) "Renal failure associated with the use of thio-tepa." J Urol, 110, p. 498-501
  2. (2001) "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)

Tepadina drug interactions

There are 265 drug interactions with Tepadina (thiotepa).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer